Don’t want emails from us anymore? Click here to unsubscribe.

A pizza chain is slipping after weaker-than-expected U.S. sales, a roofing firm is reporting strong earnings as strategic acquisitions drive future growth, and a biopharma stock is climbing after announcing a key partnership with Pfizer. Here’s what you need to know.

Metals Powering the Future (Sponsored)

AI Is Booming—But What’s Powering It Could Be Even Bigger

Investing in AI is huge—but what if you could get ahead by investing in the materials powering it all?

AI systems, EVs, and clean energy technologies rely on critical metals like copper, nickel, and PGMs. As global demand for these technologies soars, the metals behind them are becoming even more valuable.

That’s where one Canadian mining company comes in. Their high-grade polymetallic discovery in Quebec is already drawing comparisons to Russia’s Norilsk Mine—one of the world’s most valuable metal deposits.

While everyone’s chasing AI investments, those who invest in the resources fueling the revolution could be positioned for even bigger gains.

Get the full report and company details here.

Futures 📈

What to Watch

Earnings:

Economic Reports:

Food and Beverages

Domino’s Dipping On Weak Q4 Results and Poor U.S. Sales Growth

Domino’s Pizza [NYSE: DPZ] reported fourth-quarter earnings that are below analysts' expectations today, causing its stock to drop 4% in premarket trade.

The pizza chain's revenue increased by 2.9% year over year to $1.44 billion, but it missed the Wall Street forecast of $1.48 billion. Adjusted earnings per share are $4.89, slightly below the expected $4.93.

Same-store sales in the U.S. are up 0.4%, falling short of the 1.72% increase analysts had projected. However, international same-store sales are better than expected, climbing 2.7% compared to the estimated 1.63%.

For the full year, its revenue is $4.71 billion, missing the projected mark of $4.74 billion, while adjusted EPS of $16.69 is just shy of the forecasted $16.70.

Despite the underwhelming results, CEO Russell Weiner expressed confidence in the company's growth strategy, highlighting the success of its "Hungry for MORE" value platform.

The company opened 364 new stores in the fourth quarter and 775 in total for 2024.

Domino’s stock, which has gained more than 12% year-to-date, is now under close watch as investors look for potential catalysts in 2025.

Of particular interest is the impact of the company's partnership with Uber [NYSE: UBER] for third-party deliveries, as well as potential expansion to DoorDash after its exclusive deal with Uber ends.

Other initiatives, such as a revamped loyalty program and the possible launch of stuffed crust pizza, are expected to drive future sales growth.

Roofing Solutions

Owens Corning Reports Strong 2024 Growth, Eyes Further Expansion in 2025

Owens Corning [NYSE: OC] reported strong financial results for 2024, with net sales reaching $11 billion, marking a 13% increase from the prior year.

The company’s growth is partly driven by the newly acquired doors business, which contributed $1.4 billion in revenue.

Despite strong sales, net earnings are down 46% to $647 million, primarily due to strategic restructuring efforts.

The company’s adjusted EBIT is up 13%, reaching $2.0 billion, while adjusted EBITDA rose 17% to $2.7 billion. Diluted earnings per share stand at $7.37, with adjusted EPS at $15.91.

Free cash flow totaled $1.2 billion, with 51% of it—approximately $638 million—returned to shareholders through dividends and share repurchases.

CEO Brian Chambers highlighted 2024 as a “transformative year,” citing strategic initiatives such as the acquisition of Masonite International, a review of its global glass reinforcements business, and the divestment of building materials operations in China and Korea.

The company also announced plans to expand its laminate shingle production capacity in the southeastern U.S. by 2027.

Looking ahead, Owens Corning expects mid-20% revenue growth in Q1 2025, with an EBITDA margin in the low 20% range.

The company remains committed to disciplined capital allocation and continued investments to strengthen its market position in North America and Europe.

AI (Sponsored)

These Two AI Stocks Under $15 Could Be 2025’s Breakout Winners

Artificial intelligence (AI) is rapidly transforming industries—and creating lucrative opportunities for investors who spot the trends early.

From generative AI revolutionizing creativity to automation driving operational efficiency, the AI boom is just getting started—and the potential for growth in this sector is massive.

This latest research has uncovered two AI stocks trading under $15 that are flying under the radar—but not for long.

By following the link above or using any of the links provided above, you're choosing to opt in to receive insightful updates from The Wealthiest Investor plus 2 free bonus subscriptions! Your privacy is important to us. You can unsubscribe anytime. See our privacy policy for details.

These companies are positioned for significant growth as AI adoption accelerates across industries.

Get the full report and discover these two affordable AI picks.

By following the link above or using any of the links provided above, you're choosing to opt in to receive insightful updates from The Wealthiest Investor plus 2 free bonus subscriptions! Your privacy is important to us. You can unsubscribe anytime. See our privacy policy for details.

Biopharmaceuticals

Summit Therapeutics Stock Up 5% On Q4 Earnings Beat

Shares of Summit Therapeutics [NASDAQ: SMMT] are soaring more than 5% in pre-market trading after the announcement of a smaller-than-expected loss for the fourth quarter of 2024.

The biopharmaceutical firm posted a non-GAAP net loss of $0.07 per share, outperforming analysts' expectations of a $0.08 per share loss.

While revenue figures aren’t shared, the company noted a significant rise in operating expenses, which reached $65.8 million in Q4—an increase from $36.4 million in the same period last year.

The higher spending reflects increased clinical development efforts for its lead drug candidate, ivonescimab, a potential treatment for non-small cell lung cancer.

Summit's financial position strengthened considerably, with cash and short-term investments rising to $412.3 million by the end of 2024, up from $186.2 million a year earlier.

The increase is attributable to successful financing activities throughout the year.

In a significant development, Summit also announced a clinical trial collaboration with Pfizer [NYSE: PFE] to test ivonescimab in combination with Pfizer’s antibody-drug conjugates for solid tumors.

The new studies are set to begin in mid-2025, further expanding the drug’s potential applications.

With multiple Phase III trials underway and a strategic partnership with Pfizer, Summit Therapeutics remains a key player in oncology drug development.

AtlasClear Holdings, Inc. [ATCH] - Last Close: $2.35

AtlasClear Holdings, Inc., is a financial services firm specializing in trading, clearing, settlement, and banking solutions.

Its shares are up more than 100% in premarket trade because its Q4 SEC 10-Q report showed a significant turnaround in profitability for the six-month period.

Despite a net loss of $419,690 for Q4, it has a substantial six-month net income of $10.33 million, compared to just $117,022 in the same period last year.

IO Biotech, Inc. [IOBT] - Last Close: $1.10

IO Biotech is a clinical-stage biopharmaceutical company developing immune-modulatory therapeutic cancer vaccines using its T-win® platform to reshape the tumor microenvironment.

Its shares are surging before the opening bell after it presented promising preclinical data for its TGF-β-targeted peptide vaccine (IO170) at the AACR-IO Conference.

PepGen Inc. [PEPG] - Last Close: $1.37

PepGen Inc. is another clinical-stage biotech company developing next-generation oligonucleotide therapies for neuromuscular and neurological diseases.

Its shares are surging in premarket after it reported positive initial data from its FREEDOM-DM1 trial in Myotonic Dystrophy Type 1 (DM1).

Technology (Sponsored)

These 7 Stocks Will Be Magnificent in 2025

The Magnificent Seven—Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta Platforms, and Tesla—have redefined market leadership.

But as their record-breaking growth slows, the focus shifts to the next generation of industry leaders.

Analysts have identified seven global companies with the potential to rise above the rest in 2025.

These stocks are poised to surge, fueled by growing market share, robust cash flows, and innovative strategies that set them apart from the competition.

(By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time.)

Position yourself to capture the next wave of market-defining opportunities.

Click here to uncover the “7 Stocks That Will Be Magnificent in 2025” before the market catches on.

(By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time.)

Everything Else

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club